Retired RN, have been investing for about 10 years but have always been interested in the markets, just never had the time, money or focus to actively participate. For decades, was pretty good at protecting, growing, managing other people's money, either as a manager in the private health care sector or helping my husband with his business. Now, I am all in, working to build a portfolio that I can use to help my family and others. Recently resigned from a BOD position for a 501 C, due to a move to Washington State from PA. But I learned a great deal from the board members, as well as those whom we served. I never cared for health care, the margins are so small. But did do well with MNKD before the July 2014 FDA news, and am long HTA. Long MCLOX, ETE, COP. AAPL, WM, OTTR, PG, XOM, ALK, [GSK a very recent buy] and BA [also recent, July 2014]. I am in and out of PSX, BX, YORW, WTR, BMTC, INTC, and I follow negative news about some stocks so that I can learn. My biggest mistakes have been NLY and PBR.
Evaluation of the dominant assumptions and an understanding of the dynamics of the economic engine is the basis of an approach to asset allocation that provides for both a rational determination of value and an understanding of sentiment in the form of price as a measure of the irrational nature of the operational environment, an approach that is intended at once to avoid unnecessary risk while at the same time enable gradual rebalance of assets as a means to increase net worth via optimization of appreciation and long term yields. Let's call that buy low and fly high just for fun.
I have a diverse background—as a financial journalist, resident physician, mixed martial artist, painter, entrepreneur, chemistry instructor and web developer—that enabled me to pioneer the “Integrated Investing Research” approach.
I provide consulting to clients, both the retail and professional investors. I accurately forecasted many clinical trials, such as the Flint Trials for Intercept, the Ascend Trials for InterMune and the Affinity Trials MannKind, just to name a few. Through Vincata Enterprises, LLC, I helped many clients to unlock substantial values for their investments.
As an expert in biopharmaceutical analysis, I am also more than capable of analyzing any other industries. Though not shown on Seeking Alpha, I have picked an aggregate basket of outperforming stocks.
Investing in biotech is highly risky, but it can be quite rewarding when investors have an edge in data analysis. Physicians who are rigidly scientific tend to lack the analytical prowess of financial experts. Conversely, financiers usually do not possess a physician’s medical expertise. Likewise, scientists are skillful in data analysis; yet they might not be familiar with a physician’s prescribing patterns, which is a requisite to successful biotech investing.
You can visit my website at https://www.retailinvestor360.com for business inquiry.